Yazar "Aksoy, Firdevs" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: A descriptive analysis of the Eurobact II study
    (BioMed Central Ltd, 2022) Buetti, Niccolò; Tabah, Alexis; Loiodice, Ambre; Ruckly, Stéphane; Aslan, Abdullah Tarık; Montrucchio, Giorgia; Cortegiani, Andrea; Saltoğlu, Neşe; Kayaaslan, Bircan; Aksoy, Firdevs; Murat, Akova; Akdoğan, Özlem; Saraçoğlu, Kemal Tolga; Erdoğan, Cem; Leone, Marc; Ferrer, Ricard; Paiva, José-Artur; Hayashi, Yoshiro; Ramanan, Mahesh; Conway Morris, Andrew; Barbier, François; Timsit, Jean-François; Lipman, Jeffrey; Litton, Edward; Palermo, Anna Maria; Yap, Timothy; Eroğlu, Ege; Hosokawa, Koji; Yoshida, Hideki; Fujitani, Shigeki; Zand, Farid; Mahmoodpoor, Ata; Tabatabaei, Seyed Mohammad Nasirodin; Elrabi, Omar; Almekhlafi, Ghaleb A.; Vidal, Gabriela; Aparicio, Marta; Alonzo, Irene; Namendys-Silva, Silvio A.; Hermosillo, Mariana; Castillo, Roberto Alejandro; De Bus, Liesbet; De Waele, Jan; Hollevoet, Isabelle; De Schryver, Nicolas; Serck, Nicolas; Kovacevic, Pedja; Zlojutro, Biljana; Ruppe, Etienne; Montravers, Philippe; Dulac, Thierry; Castanera, Jérémy; Massri, Alexandre; Guesdon, Charlotte; Garcon, Pierre; Duprey, Matthieu; Philippart, François; Tran, Marc; Bruel, Cédric; Kalfon, Pierre
    Background: The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients. Methods: We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients’ characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models. Results: A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49–2.45). Conclusions: We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245. Registered 3 May 2019.
  • Küçük Resim Yok
    Öğe
    Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: A prospective observational cohort study
    (NLM (Medline, 2023) Aslan, Abdullah Tarık; Tabah, Alexis; Koylu, Bahadır; Köylü, Bahadır; Kaya Kalem, Ayşe; Aksoy, Firdevs; Erol, Çiğdem; Karaali, Rıdvan; Tunay, Burcu; Güzeldağ, Seda; Batirel, Ayşe; Dindar, Emine Kübra; Akdoğan, Özlem; Bilir, Yeliz; Akova, Murat
    OBJECTIVES: To uncover clinical epidemiology, microbiological characteristics and outcome determinants of hospital-acquired bloodstream infections (HA-BSIs) in Turkish ICU patients. METHODS: The EUROBACT II was a prospective observational multicontinental cohort study. We performed a subanalysis of patients from 24 Turkish ICUs included in this study. Risk factors for mortality were identified using multivariable Cox frailty models. RESULTS: Of 547 patients, 58.7% were male with a median [IQR] age of 68 [55-78]. Most frequent sources of HA-BSIs were intravascular catheter [182, (33.3%)] and lower respiratory tract [175, (32.0%)]. Among isolated pathogens (n?=?599), 67.1% were Gram-negative, 21.5% Gram-positive and 11.2% due to fungi. Carbapenem resistance was present in 90.4% of Acinetobacter spp., 53.1% of Klebsiella spp. and 48.8% of Pseudomonas spp. In monobacterial Gram-negative HA-BSIs (n?=?329), SOFA score (aHR 1.20, 95% CI 1.14-1.27), carbapenem resistance (aHR 2.46, 95% CI 1.58-3.84), previous myocardial infarction (aHR 1.86, 95% CI 1.12-3.08), COVID-19 admission diagnosis (aHR 2.95, 95% CI 1.25-6.95) and not achieving source control (aHR 2.02, 95% CI 1.15-3.54) were associated with mortality. However, availability of clinical pharmacists (aHR 0.23, 95% CI 0.06-0.90) and source control (aHR 0.46, 95% CI 0.28-0.77) were associated with survival. In monobacterial Gram-positive HA-BSIs (n?=?93), SOFA score (aHR 1.29, 95% CI 1.17-1.43) and age (aHR 1.05, 95% CI 1.03-1.08) were associated with mortality, whereas source control (aHR 0.41, 95% CI 0.20-0.87) was associated with survival. CONCLUSIONS: Considering high antimicrobial resistance rate, importance of source control and availability of clinical pharmacists, a multifaceted management programme should be adopted in Turkish ICUs.